ProCE Banner Activity

Improving ART Adherence With Point-of-Care Urine Testing: Viewpoints From Africa

Conference Coverage
Clinical Thought

Read my commentary on the use of point-of-care testing to detect TFV concentrations in the urine, including new data presented at CROI 2023 on its use to predict virologic failure in individuals receiving TAF-based ART and incorporation of the urine assay with enhanced adherence counseling as a tool to promote ART adherence among people with HIV with persistent viremia.

Released: March 20, 2023

Expiration: March 18, 2024

Share

Supporters

This activity is supported by an educational grant from

Gilead Sciences, Inc.

Janssen Therapeutics, Division of Janssen Products, LP

Merck & Co., Inc.

ViiV Healthcare

Faculty Disclosure

Primary Author

Sylvia Ojoo, CCST (UK), MRCP (UK), DTM&H (UK), DFFP (UK), MBChB

Associate Professor of Medicine
Georgetown University Medical Center
Kisumu, Kenya

Sylvia Ojoo, CCST (UK), MRCP (UK), DTM&H (UK), DFFP (UK), MBChB, has no relevant financial relationships to disclose.